ThinkSabio

$ABBV

$286.20▲ -0.9% YTD

21 SEC 13D/G filings tracked · Last updated Nov 3, 2026

Filing History
News
ABBV ▼ -0.9% - AbbVie Inc.
CP $286.20▲ -0.9%Nov 3, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026…

News
ABBV ▼ -0.1% - AbbVie Inc.
CP $294.55▲ -0.1%Nov 2, 2026 · ThinkSabio Blog

$ABBV pt 295 @ Citi from 260…

News
ABBV ▼ -0.1% - AbbVie Inc.
CP $294.55▲ -0.1%Nov 2, 2026 · ThinkSabio Blog

$ABBV pt 340 @ BMO from 300…

News
ABBV ▼ -0.3% - AbbVie Inc.
CP $290.00▲ -0.3%Oct 30, 2026 · ThinkSabio Blog

$ABBV down pm…

News
ABBV ▼ -0.3% - AbbVie Inc.
CP $290.00▲ -0.3%Oct 30, 2026 · ThinkSabio Blog

$ABBV AbbVie Q3 Earnings Adj. EPS $3.82, est. $3.74 Net rev. $17.40B, est. $17.34B Skyrizi rev. $5.78B, est. $5.74B Rinvoq rev. $2.71B, est. $2.70B Hu…

News
ABBV ▼ -0.3% - AbbVie Inc.
CP $290.00▲ -0.3%Oct 30, 2026 · ThinkSabio Blog

$ABBV - AbbVie Reports Third-Quarter 2026 Financial Results…

News
ABBV ▲ +0.5% - AbbVie Inc.
CP $286.36▲ +0.5%Oct 23, 2026 · ThinkSabio Blog

$ABBV - U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn…

News
ABBV ▲ +1.2% - AbbVie Inc.
CP $288.00▲ +1.2%Oct 22, 2026 · ThinkSabio Blog

$ABBV - AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in P…

News
ABBV ▼ -0.6% - AbbVie Inc.
CP $287.00▲ -0.6%Oct 21, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence…

News
ABBV ▲ +0.4% - AbbVie Inc.
CP $284.00▲ +0.4%Oct 20, 2026 · ThinkSabio Blog

$ABBV - AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology…

News
ABBV ▲ +1.3% - AbbVie Inc.
CP $286.88▲ +1.3%Oct 19, 2026 · ThinkSabio Blog

$ABBV - /C O R R E C T I O N - AbbVie/…

News
ABBV ▲ +1.3% - AbbVie Inc.
CP $286.88▲ +1.3%Oct 17, 2026 · ThinkSabio Blog

$ABBV AbbVie: Reports Strong Long-Term SKYRIZI and RINVOQ Remission Data in Inflammatory Bowel Disease at UEGW 2026 ? • SKYRIZI: Week 96 clinical remi…

News
ABBV ▼ -2.4% - AbbVie Inc.
CP $274.10▲ -2.4%Oct 13, 2026 · ThinkSabio Blog

$ABBV - AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients Wi…

News
ABBV ▲ +1.5% - AbbVie Inc.
CP $276.47▲ +1.5%Oct 11, 2026 · ThinkSabio Blog

$ABBV - New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disea…

News
ABBV ▲ +0.6% - AbbVie Inc.
CP $264.75▲ +0.6%Oct 5, 2026 · ThinkSabio Blog

$ABBV - Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survi…

News
ABBV ▼ -0.0% - AbbVie Inc.
CP $261.80▲ -0.0%Oct 1, 2026 · ThinkSabio Blog

$ABBV - AbbVie to Host Third-Quarter 2026 Earnings Conference Call…

News
ABBV ▼ -1.2% - AbbVie Inc.
CP $263.29▲ -1.2%Sep 30, 2026 · ThinkSabio Blog

$ABBV - AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Break…

News
ABBV ▼ -0.2% - AbbVie Inc.
CP $264.04▲ -0.2%Sep 22, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach…

News
ABBV ▼ -0.7% - AbbVie Inc.
CP $261.90▲ -0.7%Sep 21, 2026 · ThinkSabio Blog

$ABBV - AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery…

News
ABBV ▲ +0.0% - AbbVie Inc.
CP $261.77▲ +0.0%Sep 15, 2026 · ThinkSabio Blog

$ABBV - AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign…

News
ABBV ▲ +0.8% - AbbVie Inc.
CP $261.90▲ +0.8%Sep 2, 2026 · ThinkSabio Blog

$ABBV - Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care…